Astrazeneca Share Discussion Threads

[philanderer] 14/7/2023 10:49

HSBC starts AstraZeneca with 'buy' - price target 13,250 pence

[essentialinvestor] 12/7/2023 11:06

NOVECK, debt is a non issue given their cash flow, FX is weighing and
the earnings multiple demands a lot - which is why any perceived adverse news impacts the share price

[smcni1968] 12/7/2023 11:02

AstraZeneca's recent de-rating is now an entry point for investors given base business growth, UBS analysts write in a research note. "Now that last week's press release has triggered a de-rating, we are of the view that investors can come back to the stock for the performance of in-market products and their net present value that already supports the valuation leaving meaningful pipeline optionality," the analysts say. Investors can gain access to a sector-leading pipeline and growth at a reasonable price, they say. UBS lifts it stock rating to buy from hold and price target to 13,000 pence from 12,500 pence. Shares are up 0.9% at 10,168.00 pence.

[philanderer] 12/7/2023 09:46

AstraZeneca rose 1.5%, as UBS raised the stock to ’buy’... (tp 13000p)

[gregb] 11/7/2023 20:30

AZN debt / bonds have a fixed rate at the outset.

[noveckingood] 11/7/2023 19:32

High p/e, too much debt that will cost more to service and general market sell off.

So all pretty much covered apart from the forex..

[smcni1968] 11/7/2023 12:14

Seems to be the strong £ as much as anything- my RELX and Rentokil are both down too.

[thamestrader] 11/7/2023 11:17

And did you, a few weeks ago, have any thoughts as to WHY it would tank? Is it tanking for the reasons you predicted? Or are your reasons not priced in yet (ie., more tanking to come)?

It would help if Biden stopped droning on about 'big pharma ripping us all off'. Mind you, I dread to think what his meds cabinet looks like.

[noveckingood] 11/7/2023 08:30

12,11,10... 9 soon.

Anyone else notice the trend. I was derided for saying this would tank a few weeks ago....

[philanderer] 11/7/2023 00:37

Morgan Stanley’s top stock picks in the UK with the most attractive bull-bear price target skew include BAE Systems Plc, Ashtead Group Plc, 3i Group Plc, BP Plc, Smith & Nephew Plc, Haleon Plc, Prudential Plc, Rio Tinto Plc, AstraZeneca Plc, Indivior Plc, Segro Plc and SSE Plc.

[philanderer] 08/7/2023 10:44

Financial Times: Shares of pharmaceutical companies fell on Friday after the US approved first Alzheimer’s drug with brain swelling as a potential side effect.

[philanderer] 07/7/2023 17:32

That's around -10% for the week.

[philanderer] 05/7/2023 10:06

Berenberg lowers AstraZeneca target price


A lung cancer treatment from AstraZeneca (AZN) failed to meet high investor expectations but the share price drop is ‘overdone̵7;, says Berenberg.

Analyst Luisa Hector reiterated her ‘buy’ recommendation but lowered her target price slightly from £135 to £133 on the Citywire Elite Companies AAA-rated stock, which rose 2.2%, or 228p, to £106.02 on Tuesday.

The pharmaceutical giant, along with its partner Daiichi Sankyo, announced positive progression-free survival headline data for their lung cancer treatment.

‘The absence of more positive language in the press release, such as “clinically meaningful”, and the occurrence of some fatal interstitial lung disease events missed high investor expectations, resulting in AstraZeneca’s share price falling by 8%,’ said Hector.

She said the future of the drug relies on further testing, which is expected in the next six months.

‘We lower our price target to £133… a much smaller reduction than the share price move of 900p. We think the stock reaction is overdone given the overall strength of AstraZeneca’s pipeline,’ she said.


citywire.com

[philanderer] 05/7/2023 09:49

Jefferies cuts AstraZeneca price target to 10,500 (10,800) pence - 'hold'

[philanderer] 04/7/2023 10:56

Berenberg cuts AstraZeneca price target to 13,300 (13,500) pence - 'buy'

Deutsche Bank cuts AstraZeneca to 'hold' - price target 11,000 pence

[philanderer] 03/7/2023 14:01

AstraZeneca stock value falls by nearly £10bn after cancer drug trial results


Market value drops by 6% on concerns that new lung cancer drug may not be as successful as hoped

Analysts at Citi greeted the results positively overall but said the drug “may not be the home run in absolute benefit that investors had hoped for” – . Some analysts have pinned $10bn (£8bn) to $18bn (£14bn) sales estimates on the new drug.

Analysts at Barclays and Credit Suisse said shareholders had been looking for AstraZeneca to declare the results “clinically meaningful”. The company said clinical significance was a “subjective assessment” and further analysis was required to interpret the results.





Analysts at Jefferies said the results seem ‘likely to fall short of best case’.

[philanderer] 03/7/2023 10:47

Yep, lucky guess ;-)

[holts] 03/7/2023 10:34

Pure coincidence they had been quite heavily sold down before .

[steeplejack] 03/7/2023 09:52

The trial is not an unequivocal success,hence the fall.

[mirandaj] 03/7/2023 09:14

I am sure deaths occur in many trials.

[russ1983] 03/7/2023 09:09

AstraZeneca reports fatal incidents in drug trials; shares down

[russ1983] 03/7/2023 08:48

what is going on? huge plunge

[hotfinance14] 03/7/2023 08:26

There are the results and share price tanking.